stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Operating cash flow
10x Genomics's operating cash flow for fiscal 2025 was $136.1M, up 1,941.6% from $6.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $99.7M. Over the past ten years it has ranged from −$217.9M (fiscal 2020) to $136.1M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. 10x Genomics ranks 26th of 149 Medical Devices companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $136.1M | 1,941.57% |
| FY2024 | $6.7M | — |
| FY2023 | −$15.2M | — |
| FY2022 | −$33.6M | — |
| FY2021 | −$21.4M | — |
| FY2020 | −$217.9M | — |
| FY2019 | $34.6M | — |
| FY2018 | −$76.4M | — |
| FY2017 | −$10.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $15.8M | (6.72%) |
| Jun 2026 | $17.0M | (35.02%) |
| Mar 2026 | $26.1M | (35.94%) |
| Dec 2025 | $40.8M | (5.64%) |
| 29 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $3.1B |
| GMED Globus Medical, Inc. compare | $925.9M |
| PODD Insulet Corporation compare | $509.0M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $468.1M |
| BIO Bio-Rad Laboratories, Inc. compare | $468.1M |
| HAE Haemonetics Corporation compare | $344.9M |
| BRKR Bruker Corporation compare | $341.8M |
| PEN Penumbra, Inc. compare | $261.0M |
| TXG 10x Genomics | $127.1M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement